B. Riley FBR Maintains Buy on Dicerna Pharmaceuticals, Raises Price Target to $30

B. Riley FBR maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and raises the price target from $24 to $30.

Benzinga · 01/09/2020 18:47

B. Riley FBR maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Buy and raises the price target from $24 to $30.